New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 27, 2014
15:12 EDTHSP, FMS, DANOY, NSRGY Hospira in talks to acquire Danone medical nutrition business, FT says
French consumer company Danone (DANOY) has been in negotiations to sell its medical nutrition business to Hospira (HSP) in a deal said to value the unit at $5B, says the Financial Times. The deal would also allow for U.S. based Hospira to domicile its tax base in Europe in a tax strategy known as an inversion, added the Financial Times. In prior reports, Nestle (NSRGY) and Fresenius (FMS) have also been mentioned as suitors for the Danone unit. Reference Link
News For DANOY;HSP;NSRGY;FMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
11:21 EDTFMSCytoSorbents enters strategic partnership with Fresenius Medical
CytoSorbents announced that they have entered into a multi-country strategic partnership with Fresenius Medical Care AG & CO KGaA to commercialize CytoSorbents' CytoSorb therapy. Under the terms of the agreement, Fresenius Medical Care will have the exclusive rights to distribute CytoSorb for critical care applications in France, Poland, Sweden, Denmark, Norway, and Finland. This multi-year agreement is subject to annual minimum guaranteed orders of CytoSorb to maintain exclusivity.
December 12, 2014
06:44 EDTDANOYDanone backs 2014 organic growth target of 4.5%
Backs 2014 trading operating margin down less than 20 basis points like-for-like. Backs 2014 free cash flow to be between EUR1.3B-EUR1.4B. Danone said it will continue to expand capacity rapidly and build development platforms in fast-growing regions, particularly Asia and Africa. Investments made for this purpose over the past two years have resulted in a higher use of debt than in the past, at a level that could imply a credit rating one notch lower, and that is appropriate for this current period of development given the companyís sound cash-flow outlook and debt structure.
06:42 EDTDANOYDanone to keep Medical Nutrition business, Reuters reports
Subscribe for More Information
December 11, 2014
07:40 EDTFMSBofA/Merrill to hold a field trip
European Medtech Field Trip is being held in Copenhagen, Denmark on December 11-12.
07:13 EDTDANOY, HSP, FMSDanone to discuss whether to keep or sell medical nutrition unit, Reuters says
According to a source, Danone (DANOY) will hold a board meeting today to discuss whether to keep or sell its medical nutrition business, Reuters reports. Previous reports said Danone's board would decide whether to sell the unit to Hospira (HSP) or Fresenius (FMS), with Fresenius as the possible front-runner to enter exclusive talks. Reference Link
December 9, 2014
13:08 EDTHSPMerck may have paid $2B-$3B too much for Cubist, analyst says
Subscribe for More Information
08:23 EDTHSPMerck has 'no way out' of Cubist deal after court decision, says Leerink
Subscribe for More Information
08:12 EDTHSPMerck still sees Cubist acquisition neutral to modestly accretive to 2015 EPS
Merck (MRK) issued the following statement regarding the decision of the U.S. District Court for the District of Delaware. The decision, which upheld the patent for CUBICIN that expires on June 15, 2016 and invalidated four others, is subject to appeal. The company continues to believe the acquisition of Cubist (CBST) will create strong fundamental value for Merckís shareholders. The combined strength of both companies will provide both incremental and long-term value, and Merck expects the transaction to add more than $1B of revenue to its 2015 base, with strong growth potential thereafter. The courtís decision does not change Merckís expectation that the transaction will be neutral to modestly accretive to 2015 non-GAAP EPS. The company also continues to expect that the transaction will contribute mid-single digit accretion on a percentage basis to non-GAAP EPS in 2016, and will continue to be accretive thereafter.
December 8, 2014
19:00 EDTHSPCubist CEO says Cubicin patent ruling will not affect Merck transaction
Subscribe for More Information
18:24 EDTHSPOn The Fly: After Hours Movers
Subscribe for More Information
18:00 EDTHSPCubist loses bid to stop Hospira's generic Cubicin after 2016, Bloomberg says
Cubist's (CBST) patent for Cubicin that expires in June 2016 upheld by judge, Bloomberg added. Note that this morning Merck (MRK) and Cubist Pharmaceuticals announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash.
17:54 EDTHSPFour Cubist Cubicin patents invalidated as Hospira wins ruling, Bloomberg says
Subscribe for More Information
17:30 EDTHSPMerck shares lower after reports of judge decision in Cubist/Hospira case
Subscribe for More Information
17:03 EDTHSPJudge may have found in favor of Hospira in Cubist case,CNBC's Meg Tirrell says
CNBC's Meg Tirrell said in a tweet: "Whoa. $CBST Hospira decision out -- "appears judge may have found in favor of Hospira on several points," ISI's @MarkSchoenebaum says." Reference Link
08:21 EDTHSPMerck says looked at all risks, including patent litgation, before Cubist deal
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use